The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agree with you Pingu looks like an agreed privately.
You make your own mind up swimming
Defendant
HemoGenix, Inc.
Plaintiff
Hemogenyx LLC
Represented By
Robert Phillip Feinland
Meister Seelig & Fein LLP
contact info
Marc P. Misthal
Gottlieb, Rackman & Reisman
contact info
Plaintiff
Hemogenyx Pharmaceuticals plc
Represented By
Robert Phillip Feinland
Meister Seelig & Fein LLP
contact info
Marc P. Misthal
Gottlieb, Rackman & Reisman
contact info
Complaint withdrawn 8 July.
Sorted privately and we keep use of the name and use for naming patents.
The case has actually been Terminated and Dismissed by Hemo. The have decided to change the name instead of going through a long process through the courts for the name change. they have dropped the first part which used to be called Hemogenyx LLC, Hemogenyx Pharmaceuticals plc. They have now aligned the business across the board and all under one name. Crossed the T’s and dotted the i’s, makes its easier for contracts etc.
swimming....how about this..
We are about to sign a deal with the Globalco...
The case is still outstanding...so Lawyers advise us to make the
change before signing the new deal...to avoid potential complications....
That is much more likely.......
Hi scart...Looks like things are happening behind the scenes...GL!
GLA!
Swimming....I think you know they would have to report that....
As I said yesterday, I will post if I get a response....
GLA!
Oops @manifesto not @magsy, sorry too busy thinking about another BB lol
@magsy good, I’m glad we’re on the same page on this one ;-)
would even....
Swimming haha
It lost its legal case and then changed its name to the one it wouldn’t be allowed to use?
Getting their house in order me thinks.
Swimming...behave yourself...That woud have to have been notified to the market..
We can only speculate the reason why, but fair to think it is for a positive reason..IMHO!
Do you know I was thinking the same thing. Don’t want to be accused of being a ramper though
Sounds to me like the kind of thing Lawyers looking over a potential
agreement may advise....
GLA!
From a marketing and brand building point of view, this is great to see. Consistent branding across all offices and helps build universal awareness of the Hemo brand.
Getting their House in order for the Globalco deal with
an American Company??
Hemogenyx Pharmaceuticals PLC US Subsidiary Change of Name
10/07/2020 1:00pm
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
10 July 2020
10 July 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
U.S. Subsidiary Change of Name
Hemogenyx Pharmaceuticals plc is pleased to announce that its U.S. subsidiary will be renamed Hemogenyx Pharmaceuticals LLC in order to align the Company's names across entities and countries, and should always be referred to as Hemogenyx Pharmaceuticals instead of Hemogenyx by itself. The company will continue to conduct preclinical and clinical stage research and development activities to develop its own products and therapies, including therapies and treatments for blood and autoimmune diseases and viral infections. Hemogenyx Pharmaceuticals LLC will remain located at its state-of-the-art research facility in New York City.
Other than what the RNS states obviously, is there more to it?
What’s the reason do we think?